Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study.

Abstract

One hundred and sixteen Latin American type 2 diabetic patients previously only on a diet were enrolled in this multicenter, multinational, nonrandomized, noncontrolled study. Only 109 completed the study. After 8 weeks of treatment with 120 mg of nateglinide, administered prior to each meal, the postprandial (2 h) glucose concentration decreased to 85.11 +/- 5.65 mg/dl (p < 0.0001), and HbA(1c) values decreased to 1.06 +/- 0.10% (p < 0.0001). No response differences were detected in relation to age, gender, or ethnicity, but we did encounter a better response in recently diagnosed patients (<or=1 year). No serious adverse events were observed. We can, therefore, conclude that nateglinide is a well-tolerated, safe, and effective insulinotropic agent.

• Authors: Sergio Islas-Andrade, Maria Cristina Revilla-Monsalve, Evelyn Martínez de Hurtado, Luis F Chacín, Quenemari R Caminos, Hernán Yupanqui, Gloria López, Walter de la Torre, Latin American Study Group
• Journal: Pharmacology (Pharmacology) Vol. 68 Issue 2 Pg. 89-95 (Jun 2003) ISSN: 0031-7012 [Print] Switzerland
• PMID: 12711836 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2003 S. Karger AG, Basel

Chemical References

• Blood Glucose
• Cyclohexanes
• Hypoglycemic Agents
• Nateglinide
• Phenylalanine

Topics

• Blood Glucose (drug effects)
• Cyclohexanes (adverse effects, therapeutic use)
• Diabetes Mellitus, Type 2 (drug therapy)
• Female
• Humans
• Hyperglycemia (drug therapy, etiology)
• Hypoglycemic Agents (adverse effects, therapeutic use)
• Latin America
• Male
• Middle Aged
• Nateglinide
• Phenylalanine (adverse effects, analogs & derivatives, therapeutic use)
• Postprandial Period (drug effects)
• Treatment Outcome